What is Nanolive?
Headquartered in Tolochenaz, Switzerland, Nanolive specializes in the development of advanced research products designed to streamline live cell imaging and analysis. The company's core technology enables researchers to observe living cells in 3D without the need for staining or phototoxicity, providing unprecedented insights into cellular dynamics. This capability is critical for drug discovery, toxicology, and fundamental biological research, positioning Nanolive as an essential partner for pharmaceutical companies and academic institutions worldwide. By bridging the gap between traditional microscopy and modern digital analysis, the firm has established a unique market position that emphasizes precision, efficiency, and biological integrity.
How much funding has Nanolive raised?
Nanolive has raised a total of $23.3M across 3 funding rounds:
Private Equity
$2.8M
Unspecified
$514K
Series C
$20M
Private Equity (2014): $2.8M, investors not publicly disclosed
Unspecified (2016): $514K led by Swisscom
Series C (2022): $20M supported by Taiwania Capital and Swisscom Ventures
Key Investors in Nanolive
Swisscom
A leading Swiss telecommunications provider that supports technological innovation through strategic investments in high-growth digital and biotech enterprises.
Taiwania Capital
A venture capital firm focused on early-stage and growth-stage companies, specializing in sectors such as enterprise software, AI, and next-generation semiconductors.
Swisscom Ventures
The venture capital arm of Swisscom, dedicated to investing in innovative startups that align with the firm's expertise in connectivity, digital infrastructure, and advanced technology.
What's next for Nanolive?
With the recent influx of capital, Nanolive is expected to scale its commercial operations and expand its global distribution network. The strategic focus will likely center on enhancing its software-driven analytical platforms, which integrate artificial intelligence to automate complex cellular observations. As the company transitions into its next phase of maturity, it will likely prioritize the integration of its imaging hardware with cloud-based data management systems, catering to the increasing demand for high-throughput screening in the biotech industry. This strategic roadmap ensures that Nanolive remains at the forefront of the digital transformation in cellular biology, driving innovation that empowers researchers to unlock new therapeutic possibilities.
See full Nanolive company page
